First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

  1. Albiges, L.
  2. Tannir, N.M.
  3. Burotto, M.
  4. McDermott, D.
  5. Plimack, E.R.
  6. Barthélémy, P.
  7. Porta, C.
  8. Powles, T.
  9. Donskov, F.
  10. George, S.
  11. Kollmannsberger, C.K.
  12. Gurney, H.
  13. Grimm, M.-O.
  14. Tomita, Y.
  15. Castellano, D.
  16. Rini, B.I.
  17. Choueiri, T.K.
  18. Leung, D.
  19. Saggi, S.S.
  20. Lee, C.-W.
  21. McHenry, M.B.
  22. Motzer, R.J.
Revue:
European Urology

ISSN: 1873-7560,  0302-2838

Année de publication: 2022

Volumen: 81

Número: 3

Pages: 266-271

Type: Article

DOI: 10.1016/J.EURURO.2021.10.001 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus